UK Set To Launch Drug Repurposing Project
Plans Include Extended Protection Periods And New ‘Catalyst Fund’
Licensing new uses of existing medicines has several benefits over off-label use, such as offering assurances that the indication is evidence based and subject to an ongoing safety monitoring program, according to a new report.
You may also be interested in...
Coronavirus Notebook: Vaccine Shortage Fears Heightened By Safety Scares, Italian Jab Enters Phase II/III
Russia’s Sputnik V vaccine gets the all-clear in India as the COVAX initiative hits the shortages speed bump. Also, two more antibody treatments are OKd for use in COVID-19 in the UK.
Lupin and patient groups have slammed NICE’s “unprecedented” preliminary decision not to mandate funding for the repurposed rare disease treatment Namuscla for patients on England’s National Health Service who are already taking the drug. The move could set a precedent and is concerning for patients and R&D investments, says the company.
Finding new uses for older drugs is the objective of a European repurposing project that will begin in early 2020.